Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms Neurocrine Biosciences, Inc. announced new long-term data from the KINECT 4 Phase III open-label study demonstr...
EMA to relocate to Amsterdam by March 2019 Results of the Monday's vote for the European Medicines Agency relocation led to the emergence of Amsterdam as the new headquarters, beating the other fin...
With patent loss looming, Takeda knocks proposed Velcade copycats in FDA petition Takeda’s multiple myeloma blockbuster Velcade is quickly running out of patent protection, but the drug maker has f...
Steele-Richardson-Olszewski syndrome, commonly known as Progressive Supranuclear Palsy, is an uncommon brain disorder that causes serious problems for patients in terms of walking, balance and eye ...
AstraZeneca's new benralizumab helps severe asthma patients cut back on steroids AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on—or even stop—the u...
BREXIT shook the whole world when United Kingdom voted in favour of leaving the EU. After the vote, the country has been wrought in uncertainty related to political, regulatory and economic scenari...
Tesaro puts AstraZeneca on notice with early FDA nod for Lynparza rival niraparib Tesaro’s closely watched ovarian cancer drug niraparib—now dubbed Zejula—won an FDA nod on 27th March, months befor...
The high cost of pharmaceuticals, especially Biologics, has been proven as an issue in the battle to control healthcare costs. The Biologics Price Competition and the Innovation Act has put forward...
For Inflectra launch, Pfizer uses 'hybrid model' to home in on HCPs Pfizer hit the market with Inflectra, a biosimilar of Johnson & Johnson's Remicade. And with the launch came not only the beg...
In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved centrally via the European Medicines Age...
In advanced cancer patients, the most common site for the occurrence of metastasis is c...
Depression is a mental condition characterized by prolonged series of poor moods, loss ...
Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...
West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...
Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
.png)
-Featured.png)
